Search Results

Business

Ipsen to Acquire Albireo for Rare Disease Portfolio

Ipsen bolsters rare disease portfolio with acquisition of liver disease specialist Albireo.

January 9, 2023

·

1 min read

·

George Budwell

Deals

Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

Ipsen and Albireo announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.

January 9, 2023

·

27 min read

Genetown

Albireo to Participate in Jefferies London Healthcare Conference

Albireo Pharma, Inc. today announced participation in the Jefferies London Healthcare Conference in London, UK, from November 15-17, 2022.

November 9, 2022

·

1 min read

Genetown

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 20, 2022

Albireo Pharma, Inc. announced the grant to its newly appointed Chief Medical Officer, Paul D. Streck, M.D., of inducement restricted stock units to acquire 63,966 shares of Albireo’s common stock.

December 20, 2022

·

1 min read

Genetown

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 06, 2022

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, announced the grant of inducement restricted stock units to acquire 13,700 shares of Albireo’s common stock.

December 6, 2022

·

1 min read

Genetown

Albireo to Participate in Guggenheim Nantucket Therapeutics Conference

Albireo Pharma, Inc. announced participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022.

September 20, 2022

·

1 min read

Deals

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions.

March 2, 2023

·

12 min read

Genetown

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 27, 2022

Albireo Pharma, Inc., a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, announced the grant of inducement restricted stock units to acquire 13,700 shares of Albireo’s common stock.

September 27, 2022

·

1 min read

Genetown

Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference

Albireo Pharma, Inc. today announced participation in the 2022 Wedbush PacGrow Healthcare Conference August 9-10, 2022.

August 3, 2022

·

1 min read

Genetown

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 22, 2022

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators, announced the grant of inducement restricted stock units to acquire 17,300 shares of Albireo’s common stock.

August 22, 2022

·

1 min read